Clinical trials: Obesity; Drug
Overweight, Obesity
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people…
- Trial name
- NCT07587710
- Testing
- NNC0487-0111
- Where
- 2 sites in Slovakia
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity
This study is being done to learn how the study medicine affects the body and how safe it is for people who take it. The researchers will look at a number of health tests, including blood tests such as calcitonin, amylase, and…
- Conditions
- Overweight, Obesity, Healthy
- Trial name
- NCT07400679
- Testing
- PF-08653944
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity & Overweight
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases.
- Trial name
- NCT07338214
- Testing
- Petrelintide
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Obesity
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).
- Trial name
- NCT00109148
- Testing
- MK0364
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Obesity, Hypertension
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.
- Trial name
- NCT00775814
- Testing
- Candesartan and Hydrochlorothiazide, Hydrochlorothiazide (HCT)
- Where
- 24 sites in Germany
- Volunteers
- 188 people
- Sponsor
- Takeda
Drug Toxicity
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
To Evaluate the safety and tolerability after KD101 single oral dosing in healthy male subjects To Evaluate the pharmacokinetic property after KD101 single oral dosing in healthy male subjects To Evaluate the effect of food on…
- Trial name
- NCT01979380
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Obesity, Overweight
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- AMAZE 8 (NCT07400107)
- Testing
- NNC0487-0111, Semaglutide
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
- Trial name
- NCT06910839
- Testing
- PF-07976016, PF-06882961
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other…
- Trial name
- NCT07874633
- Testing
- Berobenatide
- Where
- 2 sites in China
- Volunteers
- 432 people
- Sponsor
- Pfizer
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.
- Trial name
- NCT07594093
- Testing
- REGN20934
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight,Obesity
Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin…
- Trial name
- NCT07550816
- Testing
- ZT002 injection, metformin, warfarin, ZT002 injection, rosuvastatin, digoxin
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Trial name
- AMAZE 1 (NCT07339423)
- Testing
- NNC0487-0111
- Where
- 72 sites in United States, Argentina and 7 more
- Volunteers
- 1,150 people
- Sponsor
- Novo Nordisk A/S
Overweight and/or Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.
- Trial name
- NCT07876518
- Testing
- PF-08656795
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity &Amp; Overweight
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the…
- Trial name
- NCT07065058
- Testing
- Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Overweight, Obesity
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
A phase 3, multicenter, randomized, double-blind, double-dummy, parallel-group, active-drug- and placebo-controlled clinical trial to assess the safety, efficacy and superiority of the new fixed-dose combination sibutramine…
- Trial name
- UNLIMITED (NCT05209984)
- Testing
- ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg, ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg, SIB Group Sibus (Sibutramine) 15mg
- Where
- 2 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Obesity
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Trial name
- AMAZE 12 (NCT07503210)
- Testing
- NNC0487-0111
- Where
- 72 sites in United States, Argentina and 10 more
- Volunteers
- 606 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Mental Health Disorder, Obesity
Improving Mental Health in Youth and Lowering Risk for Obesity Through a Digital Preventative Product
The goal of this study is to test the feasibility and utilization of a redesigned mobile app and health coaching platform (Vira) in youth (aged 18-25 years) with elevated depressive symptoms who are overweight/obese and/or…
- Conditions
- Mental Health Disorder, Obesity, Overweight
- Trial name
- NCT05638516
- Testing
- Vira mobile app intervention, Vira mobile app intervention + coaching
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Ksana Health